Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Kaiyuan Hui"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Carcinoma of unknown primary (CUP) is a common and complex type of tumor in clinical practice, where the primary site cannot be determined through conventional diagnostic methods, posing significant challenges for clinical diagnosis and treatment. In
Externí odkaz:
https://doaj.org/article/c6eec1bed37b4f9eb30b55b24fd48938
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
In the management of advanced non-squamous non-small cell lung cancer (NSCLC) without driver gene mutations, the current therapeutic strategies encompass chemotherapy, chemotherapy combined with anti-angiogenic therapy, and chemotherapy combined with
Externí odkaz:
https://doaj.org/article/811b7ffcf7154db9916149264082ae4a
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
B7-H3 (CD276), an immune checkpoint molecule, is overexpressed in various types of cancer and their tumor vasculature, demonstrating significant associations with adverse clinical outcomes. In addition to its well-known immune functions, B7-H3 exhibi
Externí odkaz:
https://doaj.org/article/46ddd5bc6a804f93838bf6eef5e8210a
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Malignant pleural effusion (MPE) is one of the common complications of lung cancer. The quality of life and prognoses for MPE patients are significantly compromised. Controlling the production of MPE can relieve patients’ symptoms, improve their qu
Externí odkaz:
https://doaj.org/article/92d9d534b266474b80925d7b5e9602b0
Publikováno v:
Heliyon, Vol 10, Iss 2, Pp e24668- (2024)
The mounting body of evidence demonstrates the growing importance of long noncoding RNAs in the advancement of tumors. This study aimed to investigate the molecular mechanism of lnc-SNAPC5-3:4 in non-small cell lung cancer (NSCLC). We investigated th
Externí odkaz:
https://doaj.org/article/1e6fd16d84b44c87802ca3451fbcc65a
Autor:
Lijun Liang, Kaiyuan Hui, Chenxi Hu, Yixuan Wen, Shikun Yang, Panrong Zhu, Lei Wang, Youyou Xia, Yun Qiao, Wen Sun, Jiayan Fei, Ting Chen, Fenghua Zhao, Baocheng Yang, Xiaodong Jiang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-13 (2019)
Abstract Background The efficacy and safety of multikinase inhibitor anlotinib have been confirmed in the treatment of advanced non-small cell lung cancer (NSCLC). However, the direct functional mechanisms of tumor lethality mediated by anlotinib wer
Externí odkaz:
https://doaj.org/article/a080d0980916401aa74729a02e9ca1d5
Publikováno v:
Anti-Cancer Drugs; Jun2024, Vol. 35 Issue 5, p418-425, 8p
Autor:
Chun Liu, Chenxi Hu, Ting Chen, Yanting Jiang, Xin Zhang, Hongyu Liu, Yuan Wang, Zhi Li, Kaiyuan Hui, Xiaodong Jiang
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:2867-2879
Anlotinib is an oral small-molecule multitarget tyrosine kinase inhibitor that hampers neovascularization thus providing antitumor effect. The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomized clinical study to evaluate the efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9011608701326be4ac1e1777248e7626
https://doi.org/10.1007/s00432-022-04071-5
https://doi.org/10.1007/s00432-022-04071-5
Publikováno v:
Molecular Medicine Reports
The prognosis of advanced non‑small cell lung cancer (NSCLC) is poor; therefore, identifying novel treatment strategies for patients with NSCLC is important. The present study aimed to investigate the efficacy of apatinib plus docetaxel vs. docetax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d26540029efca7995f6a57ed3a183b8
http://europepmc.org/articles/PMC7533512
http://europepmc.org/articles/PMC7533512
Publikováno v:
International Journal of Nanomedicine
Guoqing Gu,1,* Chenxi Hu,1,* Kaiyuan Hui,1 Huiqin Zhang,1 Ting Chen,1 Xin Zhang,2 Xiaodong Jiang1 1Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, 222000, Peopleâs Republic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::943e68d598138129191f15771eddae2e
https://www.dovepress.com/exosomal-mir-136-5p-derived-from-anlotinib-resistant-nsclc-cells-confe-peer-reviewed-fulltext-article-IJN
https://www.dovepress.com/exosomal-mir-136-5p-derived-from-anlotinib-resistant-nsclc-cells-confe-peer-reviewed-fulltext-article-IJN